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compared: outcome as such, duration per outcome, and cost 
per outcome. The results showed that performance indica-
tors, which also take process variability into account, reveal 
larger differences between MHS providers than mere out-
come. We recommend to use the three performance indica-
tors in a complementary way. Average pre-to-posttreatment 
change allows for a simple and straightforward ranking of 
MHS providers. Duration per outcome informs patients 
on how MHS providers compare in how quickly sympto-
matic relief is achieved. Cost per outcome informs MHS 
providers on how they compare regarding the efficiency of 
their care. The substantial variation among MHS provid-
ers in outcome, treatment duration and cost calls for further 
exploration of its causes, dissemination of best practices, 
and continuous quality improvement.
Keywords Performance indicator · Benchmarking · 
Treatment outcome · Costs · Duration
Introduction
The need to systematically gather data regarding process 
and outcome in health care to improve quality was first 
pointed out by Ellwood (1988), who suggested the creation 
of databases with treatment and outcome data by assess-
ing patients at regular intervals. Ellwood’s suggestion was 
put into practice in a nationwide benchmarking initiative in 
mental health services (MHS) in The Netherlands, which 
took off in 2010. Treatment outcome data are collected 
through routine outcome monitoring (ROM), involving 
periodic assessments of outcome with self-report meas-
ures or rating scales (de Beurs et al. 2011). Thus, outcome 
scores during and after treatment have become available on 
a large scale.
Abstract Assessing performance of mental health ser-
vices (MHS) providers merely by their outcomes is insuf-
ficient. Process factors, such as treatment cost or duration, 
should also be considered in a meaningful and thorough 
analysis of quality of care. The present study aims to 
examine various performance indicators based on treat-
ment outcome and two process factors: duration and cost 
of treatment. Data of patients with depression or anxi-
ety from eight Dutch MHS providers were used. Treat-
ment outcome was operationalized as case mix corrected 
pre-to-posttreatment change scores and as reliable change 
(improved) and clinical significant change (recovered). 
Duration and cost were corrected for case mix differences 
as well. Three performance indicators were calculated and 
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Benchmarking in the Netherlands is facilitated by the 
Dutch Benchmark Foundation (Stichting Benchmark GGZ 
or SBG; http://www.sbggz.nl) (de Beurs et  al. 2017). 
Aggregation of data collected through ROM allows for 
comparisons regarding the outcome of treatments between 
MHS providers (external benchmarking) and between 
teams or even individual therapists within MHS providers 
(internal benchmarking). Aggregated outcome informa-
tion is useful for MHS providers and professionals working 
in MHS, but can also empower patients to make informed 
decisions regarding their choice of MHS provider (Hib-
bard 2003). Collecting data on outcome of treatment and 
combining this with information regarding the clinical or 
organizational process of therapy and information regard-
ing patient characteristics, will allow us to learn what 
works best for whom (Paul 1967). Furthermore, these data 
can be used for quality improvement according to the Plan-
Do-Study-Act approach (Deming 1950, 2000) of quality 
management (see also Taylor et  al. 2014; Verbraak et  al. 
2015).
Evaluating treatment providers merely in terms of their 
outcomes is insufficient: MHS providers with similar out-
comes may still differ in time and/or efforts required to 
attain these outcomes. To get a more complete picture of the 
state of affairs and to ensure a richer and fairer comparison 
between treatment providers, process aspects of the treat-
ment, such as treatment length or costs should also be taken 
into consideration. Otherwise, practice variations in swift-
ness or efficiency may get obscured, whereas these aspects 
are highly relevant for the users of MHS—our patients—as 
well as for individual providers of care. The cornerstone 
of “value-based health care delivery” is increased value, 
that is outcome (patient based health outcomes) per money 
spent (Porter 2009; Porter and Teisberg 2006). Value (or 
quality) in health care is the best result (a beneficial out-
come) for the best price. MHS providers strive for the best 
quality and to do so they need to be informed on how they 
compare to others regarding their effectiveness per money 
spent. Patients should also be enabled to seek the treatment 
of the highest quality. Another aspect of treatment quality, 
especially relevant for patients, is how quickly positive out-
comes are achieved. Thus, for patients the duration of treat-
ment is important. With equal outcome, a MHS provider 
is preferred who realizes improvement sooner rather than 
later.
Other factors, such as demographic or clinical features 
of the patients (e.g., gender, age, pretreatment severity, 
diagnostic complexity) may also influence the outcome, 
duration and cost of treatment. These factors are in general 
beyond control of the MHS provider. For a fair comparison, 
performance indicators need to be statistically corrected for 
these potential confounders (Iezzoni 2013). Therefore, case 
mix correction is applied to outcome, duration and cost.
The present study aims to investigate various perfor-
mance indicators regarding their concordance and ability 
to discriminate between MHS providers. The main ques-
tion is to what extent duration per outcome or cost per 
outcome discriminates differently between MHS provid-
ers than outcome per se. MHS providers may differ in 
outcome as well as in duration and cost of treatment. We 
hypothesize that these indicators converge: Length and 
cost are expected to be positively associated. They offer 
different perspectives on efficiency of care delivery rel-
evant for different stakeholders. Duration per outcome—
or how long it takes to get better—is relevant for the 
patient. Cost per outcome—or how much improvement 
is achieved per dollar spent—is mostly relevant for MHS 
providers and financiers, but for patients as tax and pre-
mium payers as well. Furthermore, duration and cost may 
also be associated with outcome: MHS providers with 
better outcomes may treat shorter and cheaper, as previ-
ous research has shown for individual therapists (Okiishi 
et al. 2003). If so, combining indicators into duration per 
outcome and cost per outcome will yield larger differ-
ences between MHS providers, as compared to outcome 
without taking duration or cost into account. Variation in 
efficiency of care may be revealed more easily by taking 
these numerators into account. Thus, we hypothesize a 
more precise discrimination among MHS providers with 
an index for efficiency rather than using outcome alone.
Methods
Outline of the Study
Anonymized data were obtained in an observational study 
in which performance of MHS providers was compared. 
SBG manages a large nationwide dataset covering outcome 
of full treatment trajectories of patients treated by MHS 
providers. Of these MHS providers, eight participated in 
a pilot project to study outcome of treatment corrected for 
process indicators. The MHS providers were ranked on 
outcome: the mean of case mix corrected pre-to-posttreat-
ment change scores on symptomatology (attained after a 
full treatment trajectory). The MHS providers were coded 
henceforth 1–8 (with 1 having the best results). For the 
present study, treatment trajectories that started in 2013 or 
2014, and concluded in 2014 were selected. Only treatment 
trajectories with complete pre- and posttreatment data were 
included (49% of all remunerated treatments, see Table 1). 
The maximum treatment length was 2 years, and covered 
90% of all monitored treatments. For technical reasons, 
longer treatments (the remaining 10%) were excluded from 
the present study.
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Participants and Patients
The eight providers who participated in the study are 
among the 16 largest Dutch MHC institutes in terms of 
their yearly overall turnover and represent the various 
types of MHC providers in The Netherlands well: Six are 
large institutes where many clinicians—predominantly 
psychologists and psychiatrists—provide inpatient and 
outpatient care to all types of psychiatric disorders; two 
specialize in outpatient care of predominantly mood, anxi-
ety, and personality disorders. The latter two providers 
are both franchise organizations operating nationally; one 
of these provided nation-wide data, the other provided 
data from a single municipality. There is quite some vari-
ation among providers regarding structural factors (some 
providers are large institutes providing a mix of inpatient 
and outpatient care, whereas other provide only outpatient 
treatment and claim to abide better to clinical guidelines 
for short problem-focused treatments) There is variation in 
process factors as well (possibly due to different theoretical 
approaches). Thus, we may expect variance in outcome and 
efficiency as well.
In order to homogenize the study sample and improve 
comparability of results, we selected patients with DSM-
IV (American Psychiatric Association 1994) depressive 
disorders and/or anxiety disorders. The patients received 
predominantly outpatient psychotherapy and/or pharmaco-
therapy. Table 1 presents an overview of characteristics of 
included patients.
Outcome Measures
Treatment outcome was assessed through the repeated use 
of various reliable and valid self-report questionnaires for 
general psychopathology. Five questionnaires were used: 
the symptomatic distress scale of the outcome question-
naire (OQ-45; Lambert et al. 2004); the total score of the 
depression anxiety stress scales (DASS-21; Lovibond 
and Lovibond 1993); the total score of the brief symptom 
inventory (BSI; Derogatis 1975); the total score of the 
short symptom list (Korte Klachtenlijst—KKL; Appelo 
2006), and the problems subscale of the clinical outcomes 
in routine evaluation-outcome measure (CORE-OM; Evans 
et al. 2002). Scores on questionnaires were standardized to 
a common metric: T-scores with at pretreatment M = 50; 
SD = 10 (McCall 1922). In addition, scores were trans-
formed in order to get a normal distribution and a true 
interval scale, required for calculation of pre-to-posttreat-
ment change scores (de Beurs 2010). In previous studies 
we compared these instruments on their responsiveness to 
change and found some variation, amounting to a 10–15% 
difference in outcome between pairs of instruments (de 
Beurs et al. 2012).
Methods for Rendering Treatment Outcome
Treatment outcome was defined by the pre-to-posttreatment 
difference in severity of symptoms (Delta T or ΔT). Post-
treatment scores and ΔT were corrected for case mix dif-
ferences. The continuous nature of the T-scale optimizes 
statistical power and simplifies ranking of MHS providers 
(de Beurs et al. 2016). However, a limitation of ΔT is that 
it produces a rather abstract figure, which does not yield 
any information on quality and nature of a patient’s clinical 
end state. An alternative method to denote treatment out-
come was proposed by Jacobson and Truax (1991). Their 
two core concepts are the reliable change index  (JTRCI) and 
clinical significance  (JTCS). For  JTRCI it should be unlikely 
Table 1  Characteristics of the patients from the MHS providers
NA not available due to missing data
a ROM = ROM-response (percentage of treatments with complete pre-and posttreatment data) according to the benchmark reporting module 
(BRaM), website of SBG
b Bonferroni corrected pairwise comparisons: 1 > 2, 4, 6; 3 > 2, 5, 6, 7; 4 < 2, 3; 8 < 1 to 7
Provider N ROMa Female DEP ANX Age SES URB GAF Pretreatment  Tb
% % % % M SD M SD M SD M SD M SD
1 104 77.6 72.1 52.9 47.1 37.0 11.7 3.43 1.45 2.77 1.13 58.1 6.8 54.9 9.1
2 1412 56.7 69.1 51.3 48.7 38.0 13.8 3.17 1.46 2.36 1.17 54.6 6.8 52.5 9.5
3 462 50.8 60.8 61.5 38.5 39.1 12.8 3.15 1.06 3.05 1.18 49.8 6.1 54.4 9.2
4 406 43.2 61.3 51.0 49.0 39.5 12.6 2.69 1.34 3.17 1.16 51.7 6.2 50.6 9.1
5 265 28.3 63.8 61.9 38.1 45.5 16.1 2.67 1.36 2.33 1.07 57.7 12.4 51.8 8.4
6 253 31.9 59.7 54.5 45.5 41.5 13.1 2.78 1.05 3.35 1.03 56.0 9.3 51.1 10.4
7 178 26.4 74.2 49.4 50.6 33.9 12.4 NA NA 3.33 1.63 54.7 7.4 51.3 8.7
8 511 51.3 59.7 53.4 46.6 42.0 15.3 3.69 1.12 2.34 0.98 61.4 10.4 48.4 9.0
Total 3591 49.1 65.1 53.8 46.2 39.4 14.0 3.13 1.35 2.62 1.19 55.0 8.6 51.8 9.4
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(p < .05) that change as expressed in the difference between 
the pre- and post-test score is due to measurement impreci-
sion. For the  JTRCI a value of ΔΤ = 5.0 is used that repre-
sents half a standard deviation and is considered the mini-
mal clinically important difference (de Beurs et  al. 2016; 
Norman et al. 2003; Sloan et al. 2005). Patients with a case 
mix corrected ΔT > 5 were considered improved. To meet 
clinical significant outcome or recovered status a patient’s 
score needs to be changed within the criteria of the reli-
able change index  (JTRCI), but also the posttreatment score 
needs to be within the functional range  (JTCS). For  JTCS 
a cutoff point of T = 42.5 was determined (de Beurs et al. 
2016). Combined with case mix correction, for  JTRCI&CS 
the case mix corrected posttreatment score needs to be 
T < 42.5 as well as more than five points less than the pre-
treatment T-score.
Cost and Treatment Duration
Costs were defined as direct and indirect cost of therapist 
time for patient care. It involves the costs for diagnosis 
treatment combinations specified in reimbursement rates 
in the Dutch fee-for-service system (diagnose-behandeling-
combinaties or DBCs as they are called in Dutch (Tan et al. 
2012). These data are embedded in 13 treatment time cate-
gories of the DBC-code system. Four categories cover short 
treatment (0–99, 100–199, 200–399, and ≥400 min). Nine 
categories cover more comprehensive treatment, 250–799, 
800–1799, 1800–2999, 3000–5999, 6000–11,999, 
12,000–17,999, 18,000–23,999, 24,000–29,999, and 
≥30,000  min). These categories were recoded into 13 
monetary values based on the cost rates for Dutch MHS in 
2014. The cost of treatment for the second year was added 
to the cost of the first year to arrive at the sum of cost for 
the complete treatment trajectory for each patient. Cost for 
psychiatric hospitalizations, for medications, or for treat-
ment by GP’s are not included in this study, as it focusses 
on outpatient treatments provided by psychiatrists and psy-
chologists who are employed by MHS providers. The cost 
of a treatment trajectory was on average about 3150 euros 
(see Table 3).
Treatment duration was calculated in weeks, based on 
the interval between the date of opening the DBC (usually 
the first face-to-face diagnostic contact of the patient with 
the intaker/therapist) and the date of the last face-to-face 
treatment session. Thus, a possible waiting period between 
the intake and first treatment session was included in the 
treatment duration. Both SBG and the Dutch Healthcare 
Authority (NZa, https://www.nza.nl/organisatie/sitewide/
english) provide guidelines and detailed specifications on 
timing of assessments, on how the start and conclusion date 
of treatments should be recorded, and on how to log treat-
ment time (the number of minutes). As scrutiny is critical 
for a fair remuneration system, compliance is monitored 
through yearly audits by accountants.
To examine the improvement rate over time, duration 
per outcome was calculated by dividing standardized dura-
tion by standardized outcome (both variables transformed 
to T-scores, to avoid 0-scores in the nominator and denomi-
nator). The resulting indicator had value 1 when treatment 
duration and outcome are in balance. When the indicator 
value was <1 it took less time to achieve a similar outcome 
or a better outcome was achieved in the same time. A value 
above 1 indicated that it took more time or less improve-
ment was achieved. In a similar vein, cost per outcome 
was calculated by dividing standardized cost by standard-
ized outcome. Thus, the longer and/or more expensive the 
treatment and/or the lower the ΔT (a worse outcome), the 
higher these indicator values will be. Both indicators were 
calculated for each patient (patient-oriented).
In addition, duration and cost per outcome was calcu-
lated for each MHS provider by dividing the mean scores 
on these variables. In addition, duration and cost per reli-
ably improved patient, and duration and cost per recov-
ered patient were calculated by dividing the average cost 
of the treatment for each MHS provider by the propor-
tion of patients with reliable improvement  (JTRCI) or with 
recovery  (JTRCI&CS). For example, if an MHS provider is 
able to achieve a 25% recovery rate and their average cost 
of treatment is 2500 euros, cost per recovered patient is 
2500/25% = 10,000 euros; if the recovery rate is 50%, the 
indicator cost per recovery would be 5000 euros. In a simi-
lar way, duration per reliably improved patient was calcu-
lated by dividing the average duration by the proportion 
of patients with reliable improvement  (JTRCI). If the aver-
age duration of treatment for a MHS provider is 30 weeks 
and the improvement rate is 50%, the indicator “duration 
per improved patient” is 30/50% = 60 weeks; with 75% 
improved patients the indicator value is 30/75% = 40. These 
six indicators are “service provider-oriented”, as they are 
derived from the average scores on performance indicators 
achieved by the MHS providers.
Case Mix Correction
As we expected differences in case mix among MHS pro-
viders, various demographic and clinical variables were 
collected. Socio-economic status (SES) and urbanization 
was coded in five levels (higher scores indicate higher 
urbanization or higher SES level) and was derived from the 
first four digits of the postal codes of patients. Diagnostic 
information was obtained according to the DSM-IV (Amer-
ican Psychiatric Association 1994), pretreatment disorder 
severity was operationalized with the pretreatment T-score, 
and pretreatment functioning with the global assessment of 
functioning (GAF) scale of the DSM-IV.
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There were substantial differences between pro-
viders in pretreatment severity of the patients (F (7, 
3583) = 19.03, p < .001, η2 = 0.04) and GAF-score (F 
(7, 3561) = 91.99, p < .001, η2 = 0.15). Furthermore, 
the gender distribution differed between providers (χ2 
(7) = 35.06; p < .001), and their populations also differed 
in age (F (7, 3583) = 17.53, p < .001, η2 = 0.03), socio-
economic status (F (6, 3337) = 32.12, p < .001, η2 = 0.06), 
and urbanization (F (6, 3344) = 63.99, p < .001, 
η2 = 0.10). See Table 1 for full details including Bonfer-
roni corrected multiple comparisons of MHS providers 
on pretreatment severity.
As the populations of MHS providers diverged, all 
indicators (outcome, duration, and cost) were corrected 
for case mix differences (Iezzoni 2013). In previous anal-
yses, the pretreatment score appeared the most impor-
tant case mix variable, explaining about 25% of variance 
in the posttreatment score (Warmerdam et  al. 2016). A 
higher pretreatment level predicts both a higher posttreat-
ment level as well as a larger ΔT, as it leaves more room 
for improvement. In addition, outcome was corrected for 
two other predictors: GAF score and SES. For both items, 
a lower score was associated with worse outcome. Other 
variables (e.g. gender or urbanization) were not associ-
ated with outcome. This model explained a substantial 
29.0% of posttreatment variance in the national dataset 
(N = 29,395) (Warmerdam et  al. 2017). Case mix cor-
rected ΔT was calculated by correcting the posttreatment 
level for case mix variables.
Duration was corrected for initial severity level, func-
tioning, age, gender, and diagnoses. Many of these vari-
ables showed different associations with outcome. The 
diagnoses “major depressive disorder, single episode” and 
“other mood disorder” were associated with shorter treat-
ment; OCD was associated with longer treatment. A higher 
severity and worse functioning at pretest were associated 
with longer treatment. A higher age and male gender pre-
dicted longer treatment. This model explained only 2.7% of 
variance in duration.
Cost was corrected for initial severity level, function-
ing, age and for the diagnoses “major depressive disorder, 
recurrent” and OCD. In all these variables, a higher score 
was associated with higher costs. The model explained a 
modest 8.4% of variance in cost, which is less than typi-
cally found in MHC (Hermann et al. 2007; Iezzoni 2013). 
This may be explained by diminished variance in the pre-
dictors, due to selection of a diagnostically homogenous 
patient group and by diminished variance in the cost vari-
able, as only outpatient treatments were selected. Finally, 
potentially relevant variables, such as comorbidity, were 
assessed with insufficient reliability to be included; others, 
such as education or living situation had to many missing 
values (>25%).
Statistical Analysis
The various performance indicators were compared in 
patient-oriented and service provider-oriented data. First, 
treatment outcome of patients was compared among ser-
vice providers with a repeated measures ANOVA. After 
this omnibus test, we performed post-hoc tests (all possible 
pairwise comparisons between providers with a Bonferroni 
correction for multiple testing) to ascertain which service 
providers had statistically different outcomes. Mean treat-
ment duration, cost of treatment, duration per outcome and 
cost per outcome of patients were also compared among 
service providers with ANOVA. Differences in propor-
tions of recovered and improved patients between service 
providers were tested with Chi-square tests. The associa-
tion between duration, cost, and outcome was assessed with 
correlational analysis (Pearson r). Next, service providers 
were rank ordered according to each performance indicator 
(service provider-oriented data). To investigate discordance 
among indicators (or their potential redundancy, because of 
concordance) we calculated the correlation between rank 
ordering of the service providers (Spearman rho rank cor-
relation coefficient). Finally, we investigated the ability 
of the indicators to discriminate between service provid-
ers with stepwise discriminant analysis. As indicators are 
correlated (as cost and duration do), two stepwise discri-
minant analyses were done: one focusing of cost and the 
other on duration. The option of stepwise entry based on 
Wilks Lambda was chosen, entering discriminant variables 
one by one only after they appear to improve the discrimi-
nant function significantly. The classification variable is 
the service provider, indicators are independent variables, 
and each analysis tests which indicators discriminate best 
between service providers. The first variable to enter maxi-
mizes separation among the groups, the next to enter adds 
the most in further separating the groups, etc.
Results
ANOVA of case mix corrected ΔT-scores revealed a 
significant difference among service providers: F (7, 
3583) = 38.52, p < .001, η2 = 0.070. Pairwise comparisons 
showed that providers 1, 2, and 3 differed from all the other 
service providers (larger ΔT scores), and service provider 8 
differed from 4 to 5 (smaller ΔT score). We refer to Table 2 
for an overview of the corrected ΔT-scores of the service 
providers. Outcome diverges considerably between ser-
vice providers from ΔT = 17.02 for service provider 1 to 
ΔT = 5.75 for service provider 8, an almost threefold differ-
ence in average reduction of symptomatology.
Table  2 also presents proportions of improved and 
recovered patients for the service providers and their 
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subsequent ranking. For the categorical outcomes of 
 JTRCI and  JTRCI&CS, Chi-square tests revealed differ-
ences between service providers. For the  JTRCI the Chi-
square test was χ2 (7, Ν = 3591) = 120.0, p < .001 and for 
the  JTRCI&CS χ2 (7, Ν = 3591) = 119.2, p < .001. Visual 
inspection reveals that more patients are reliably changed 
and recovered by service providers 1 and 2 and less by 
service providers 6 and 7. Service providers 4 and 8 are a 
tie. The ranking of service providers according to ΔT and 
JT-indices generally converges (Spearman rho = 0.96; 
p < .01; N = 8 between ΔT and  JTRCI and rho = 0.97; 
p < .01; N = 8 between ΔT and  JTRCI&CS, respectively).
Table  3 presents results regarding duration and costs 
for the eight providers. For the comparison of the mean 
treatment duration among service providers, a one-way 
ANOVA was performed which showed that the service 
providers differ significantly, F (7, 3591) = 41.56, p < .001, 
η2 = 0.075. Post-hoc tests showed that service provider 1, 2, 
5, and 6 treated significantly shorter than service providers 
3, 4 and 8. Moreover, 2 treated shorter than 5, 6, and 7; 3 
Table 2  Treatment outcome 
(case mix corrected ΔT-score) 
and percentages of improved 
and recovered patients for eight 
providers
JTRCI =
Mpretest−Mposttest
SEM
; SEM = SD ×
√
1 − rii; JTCS =
SDpreMpost+SDpostMpre
SDpre+SDpost
; JTRCI& CS = JTRCI ∧ JTCS;
Mposttest, Mpost = case mix corrected posttest score
JTRCI&CS reliable change and clinical significance
a Bonferroni corrected pairwise comparisons: 1 to 3 > 4 to 8; 4, 5 > 8
b Ranked from lowest to highest ΔT score, from more to less improved and from more to less recovered 
patients
Provider ΔT-scorea Improved  (JTRCI) Recovered  (JTRCI&CS)
M SD
1 17.02 13.11 76.9 53.8
2 14.45 14.10 0.1 53.9
3 13.01 11.74 63.0 36.6
4 9.40 11.49 60.3 40.6
5 8.87 11,31 59.2 35.5
6 8.41 13.25 54.5 33.6
7 6.07 10.81 52.2 29.8
8 5.75 12.32 60.3 36.0
Total 11.28 13.31 66.4 43.6
Rank  orderb 1-2-3-4-5-6-7-8 1-2-3-4/8-5-6-7 2-1-4-3-8-5-6-7
Table 3  Mean duration and costs of treatment per provider (case mix corrected, patient oriented data)
a Bonferroni corrected pairwise comparisons: For duration: 1, 2, 5, 6 < 3, 4, 8; 2 < 5, 6, 7; 7 < 4, 8. For cost: 1 < 3, 6, 7, 8; 2 < 4 to 8, 3 > 4. For 
duration per outcome: 1, 2 < 3 to 8, 8 > 3 to 6. For cost per outcome: 1, 2 < 3 to 5; 1 to 4 < 6 to 8; 5 < 7, 8
b Standardized duration divided by standardized outcome
c Standardized cost divided by standardized outcome
d Providers are ranked from low to high duration and from low to high cost
Provider Duration (weeks)a Cost (euros)a Duration/outcomeb Cost/outcomec
M SD M SD M SD M SD
1 39.55 16.04 2647.14 1520.49 0.93 0.21 0.93 0.19
2 34.86 16.16 1826.70 854.18 0.94 0.29 0.93 0.25
3 47.56 24.74 4315.62 5174.04 1.07 0.32 1.07 0.34
4 47.00 17.87 3508.93 3779.08 1.13 0.29 1.09 0.31
5 40.72 23.54 3686.32 3520.76 1.06 0.29 1.10 0.27
6 39.76 23.27 4409.81 6812.65 1.09 0.45 1.17 0.50
7 42.41 20.86 4376.40 4289.52 1.14 0.34 1.20 0.38
8 48.25 22.53 4195.18 4229.26 1.22 0.37 1.20 0.36
Total 41.06 20.71 3143.51 3777.32 1.05 0.34 1.05 0.33
Rank  orderd 2-1-6-5-7-4-3-8 2-1-4-5-8-3-7-6 1-2-5-3-6-4-7-8 1/2-3-4-5-6-7/8
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and 4 longer than 5 and 6, 4 longer than 7, and 8 longer 
than 5 to 7. Average treatment duration ranges from 34.86 
to 48.25 weeks, a 1.4-fold difference.
Regarding cost of treatment, a one-way ANOVA 
showed that the service providers differ significantly, F (7, 
3591) = 49.09, p < .001, η2 = 0.088. Post-hoc tests indicated 
that service providers 1 and 2 differ from 6 to 8 (lower 
costs), service provider 1 differs from 3 (lower costs), 
service provider 2 differs from 4 to 5 (lower costs) and 3 
differs from 4 (higher costs). As cost data were skewed 
to the right, we also performed a Kruskal–Wallis test 
revealing again a statistical difference between providers 
(χ2(7) = 565,54, p < .001), with a similar ranking (2-1-6-4-
3-5-7-8). Table  3 shows the average costs of service pro-
viders, which vary considerably, ranging from M = 1827 
to 4410 euros. This revealed a 2.4-fold difference between 
service providers with the lowest and the highest average 
cost per treatment.
Table  3 also presents results of the indices combin-
ing duration or cost with outcome. Service providers dif-
fer significantly on the duration per outcome indicator: F 
(7, 3591) = 50.61, p < .001, η2 = 0.090. Post-hoc tests indi-
cated that service provider 1 and 2 scored better on this 
index than all other service providers. Service provider 7 
and 8 differed from all other service providers showing 
longer treatment duration (see Table 3). Service providers 
also differ significantly on the cost per outcome index: F 
(7, 3591) = 59.67, p < .01, η2 = 0.104. Post-hoc tests indi-
cated that again service provider 1 and 2 had lower cost per 
outcome compared to most of the other service providers. 
Eight had higher costs per outcome than the service provid-
ers 1 to 5.
Next, for each service provider mean duration divided by 
mean outcome, duration and cost per improved and dura-
tion and cost per recovered patient were calculated. Table 4 
presents an overview of how service providers ranked on 
these indices. The results reveal a difference between ser-
vice providers on the index duration per outcome, ranging 
from 2.32 to 8.39 weeks per ΔT unit (≈0.1 SD). Thus, these 
service providers diverge by a factor 3.6. Put differently: it 
takes on average 3.6 times longer to achieve one ΔT-point 
improvement for service provider 8 compared to service 
provider 1. Variation in treatment duration per improved 
patient among service providers is also substantial, with the 
fastest and the slowest service provider differing by a fac-
tor 1.8 (45.81 vs. 81.25 weeks for service provider 2 and 
8, respectively). In duration per recovered patient these 
service providers diverge by a factor 2.2 (64.68 vs. 142.32 
weeks).
Cost per outcome ranges between service providers from 
€ 126.45 for service provider 2 to € 729.23 per ΔT unit for 
service provider 8, a 5.8-fold difference between the most 
and the least cost-efficient service provider (see Table  4). 
In terms of cost per reliably changed or recovered patient, 
service providers differed as well. Here, service provider 2 
diverges the most from service provider 7 with for change 
or recovery, a factor 3.5 and 4.3, respectively. Thus, to 
achieve recovery is on average almost 4.3 times costlier 
with service provider 7 (14 686 euros) than with service 
provider 2 (3 389 euros).
Next, we investigated associations among indicators. 
Pearson correlation of patient-oriented data between dura-
tion and costs showed that duration of treatment was sub-
stantially related to the cost of treatment (r = .42; p < .001; 
N = 3591). There was no association between outcome and 
Table 4  Overview of case mix corrected duration and costs per outcome indicator (provider-oriented data)
a Providers are ranked from low to high duration and from low to high cost
b Highest value divided by the lowest value
Provider Duration per Cost per
ΔT-unit Improved patient Recovered patient ΔT-unit Improved patient Recovered 
patient
1 2.32 51.43 73.51 155.49 3 442 4 920
2 2.41 45.81 64.68 126.45 2 400 3 389
3 3.66 75.49 129.95 331.72 6 850 11 791
4 5.00 77.94 115.76 373.38 5 819 8 643
5 4.59 68.78 114.70 415.56 6 227 10 384
6 4.73 72.95 118.33 524.56 8 091 13 124
7 6.99 81.25 142.32 721.14 8 384 14 686
8 8.39 80.02 134.03 729.23 6 957 11 653
Total 3.64 61.84 94.17 278.68 4 734 7 210
Rank  ordera 1-2-3-5-6-4-7-8 2-1-7-6-4-3-5-8 2-1-7-3-6-4-5-8 2-1-3-4-5-6-7-8 2-1-3-7-4-5-6-8 2-1-3-7-5-4-6-8
Factorb 3.5 1.8 2.2 5.8 3.5 4.3
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duration of treatment (r = −.03; p = .05; N = 3591). We 
detected a minor negative association between outcome 
and cost (r = −.05; p < .01; N = 3591). The costlier treat-
ments yield slightly lower ΔT scores. Table  5 presents 
Spearman rho coefficients of service provider-oriented 
data for the concordance between performance indicators 
in rank order of service providers. The ranking of service 
providers according to ΔT generally converges with the 
ranking according to cost-indicators, but less so with dura-
tion. Some associations are not statistically significant, due 
to the small N = 8 for service providers. There is a high 
concordance between ranking based on ΔT and cost per 
outcome.
Finally, we compared the ability of indices to discrimi-
nate between service providers with stepwise discriminant 
analysis. The first discriminant analysis evaluated three 
indicators: outcome, cost, and cost per outcome. A stepwise 
discriminant analyses revealed that the cost per outcome 
indicator entered the discriminant function first (canonical 
correlation r = .371), followed by cost (r = .142), and out-
come (r = .063). Apparently, and in line with the other find-
ings, cost per outcome maximizes separation among the 
service providers. The discriminant function could classify 
41.9% of the cases to the correct service provider. The sec-
ond discriminant analysis evaluated outcome, duration and 
duration per outcome. Again, the index combining infor-
mation on duration and outcome entered first (canonical 
correlation r = .349), followed by duration (r = .161) and 
outcome (r = .076). This discriminant function classified 
41.8% of the cases to the correct service provider.
Discussion
The prime aim of the present study was to compare perfor-
mance indicators on how they distinguish between service 
providers. Specifically, we investigated performance indi-
cators that combine outcome with treatment process vari-
ables, such as duration and costs of treatment, as compared 
to looking at outcome alone. When comparing the perfor-
mance indicators, it seems at first glance that information 
on cost does not matter much for ranking, considering the 
high association between ΔT and cost per ΔT (Table  5). 
Including cost in the performance indicator does however, 
amplify the differences among service providers. They 
diverge more on duration per ΔT (a 3.5-fold difference 
between the highest and lowest indicator value) or cost per 
ΔT (a 5.8-fold difference) than on ΔT alone (a threefold 
difference). In other words, differences between service 
providers in performance are larger when also duration and/
or cost are considered. With categorical outcomes, combin-
ing costs and outcomes augments differences among ser-
vice providers as well. The service provider with the best 
results is 4.3 times more efficient than the provider with the 
least favorable results, when we look at the cost-for-recov-
ery indicator, which is on average € 3389 against € 14,686 
per recovered patient. The results regarding the association 
among performance indicators reveal that outcome and cost 
per outcome lead to more similar rankings than outcome 
and duration per outcome, especially when we consider 
cost per improved or cost per recovered patient. Perfor-
mance indices do not overlap completely; rather, they add 
information onto each other. Finally, discriminant analyses 
revealed that the combined indices of cost per outcome and 
duration per outcome maximized separation among ser-
vice providers. Apparently, efficiency discriminates better 
between service providers than outcome only and yields a 
more informative and useful performance indicator.
The cost per outcome indicator allows for a straight-
forward ranking of the service providers regarding their 
efficiency. However, cost per outcome is by itself a rather 
abstract concept and not very appealing from a clinical 
perspective. Looking at the cost of improvement or recov-
ery is less abstract and a more informative way to look at 
efficiency. Yet, a potential drawback of looking at outcome 
categorically is that statistical power to find differences 
among groups diminishes (Fedorov et  al. 2009), which 
could prove problematic when smaller datasets are used. 
We suggest that these indices be used to illustrate findings, 
by examining first the general picture provided by the cost 
per outcome based on the continuous scale (ΔT) and then 
moving on to the more appealing cost per reliable improve-
ment or cost per recovery.
At the service provider level duration and cost are nega-
tively associated with outcome. Service providers who pro-
vide shorter and less expensive treatments also tend to have 
better outcome in terms of pre-to-posttreatment change in 
severity of symptoms. For example, service provider 8 is 
procuring the highest cost and is also the one with the low-
est improvement stats. Consequently, service provider 8 is 
consistently last in the rankings based on the ratio of cost 
per outcome across the indices. On the other hand, ser-
vice provider 2 has the least costs while showing the high-
est number of improved patients and is consistently first in 
the ranking based on the ratio of cost per outcome across 
Table 5  Association of ranking according to DT with ranking 
according to other performance indicators (N = 8)
ns not significant
*p < .05; **p < .01 (2-tailed)
Duration 0.57ns Cost 0.69ns
Duration per DT 0.88** Cost per DT 0.98**
Duration per improved 0.57ns Cost per improved 0.83*
Duration per recovered 0.67ns Cost per recovered 0.81*
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indices. By and large, the service providers with the high-
est change scores (the best results) also treat shorter and 
procure lower costs, despite case-mix correction of these 
indicators.
At the patient level, irrespective of service provider, 
the association between outcome and duration or cost is 
no longer found. A daring explanation for this disparity 
in findings is that the association between duration or cost 
with outcome is not contingent upon patient characteristics, 
but rather on service provider characteristics. Quite consist-
ently, the service providers who rank first and second have 
better results than the other service providers, both in post-
treatment outcome and in the proportion of recovered or 
merely changed patients. In contrast, the service provider 
who ranked last had the lowest scores on all three outcome 
indices. This service provider had a smaller ΔT score and 
less patients in the recovered or changed categories.
It is unknown which factors cause variation in effi-
ciency and outcome. Service providers differ in the kind 
of treatments that are offered (e.g., in accordance with 
evidence based guidelines vs. experience based), how 
well treatments are provided by professionals and assign-
ments executed by patients (treatment integrity), flexibil-
ity in treatment intensity, how frequently ROM is applied 
and which measure is used, and in institutional culture, 
or “corporate” management (Anderson 2006), to mention 
a few. For instance, some service providers do not offer 
inpatient treatment whereas others do. Service providers 
who do not provide inpatient treatment may refer more 
severe patients out which may boost their results. Some 
service providers, apply ROM only at pre- and posttreat-
ment, whereas others monitor more frequently, allowing 
for timely adjustment of treatments that are “not on track” 
and likely result in treatment failure (Lambert 2010). 
Organizational differences between service providers will 
also influence treatment duration, cost, and outcome. For 
example, some service providers explicitly aim for short 
protocolled cognitive-behavior therapy treatments (usually 
concluded within a year) or put extensive effort in timely 
ending of unproductive treatments through so-called “out-
take” teams (Hoogduin et al. 1997; Verbraak and Hoogduin 
2013). Termination of treatment can be difficult, especially 
when insufficient improvement has been achieved, as it 
runs counter to the professional ethos of caring therapists 
(Cohen et al. 2006). Yet, continuing an unproductive treat-
ment is not beneficial to the patient either and diminishes 
the efficiency of care.
Comparing outcomes between service providers calls for 
caution and prudence given the observational nature of the 
present data. Firstly, service providers used different out-
come measures and had different rates for the complete-
ness of pre-to-post assessments. Furthermore, nonrandom 
missingness of outcome data (e.g., because patients who 
prematurely terminate treatment are less inclined to comply 
with posttest assessments) may bias the results of provid-
ers, reduce information validity, and hamper comparison 
(Cuddeback et  al. 2004). Also, service providers differ in 
the treatment modalities they offer, with some provid-
ing at least some inpatient service, inducing substantial 
divergence in cost, and potentially influencing the type of 
patients referred to them. In addition, service providers 
vary substantially regarding the patient population they 
serve, their so-called case mix. Some patients are harder 
to treat than others; they require more intensive treatment 
with longer and/or higher costs, but may still have worse 
outcomes. Although we did correct all indicators of out-
come, duration and cost for known case mix differences 
among service providers (Iezzoni 2013; Warmerdam et al. 
2016), one could still argue that case mix correction is a 
statistical band-aid, never perfect, and potentially deficient. 
Relevant case mix variables may have been overlooked or 
are still unknown. For instance, prior episodes of psychopa-
thology or prior treatments may be an impediment to good 
outcome, but this information was not available. The only 
way to fully rule out the influence of known and unknown 
pretreatment differences between compared populations 
is a true experimental design with randomization (Hulley 
et al. 2013). As no randomization of patients to service pro-
viders has taken place in this observational study, results 
should be interpreted with outmost caution regarding com-
parative performance of service providers. Only a truly 
experimental study design will yield conclusive answers to 
the question of how cost or duration of treatment and out-
come are interrelated and whether duration of treatment is 
dependent on patient or service provider characteristics.
The main strength of this study is the use of real life 
data, not acquired in a clinical trial with selected patients, 
but under the daily circumstances of clinical care provi-
sion. This allows to reach conclusions that are based on 
real-life clinical practice and increases our confidence in 
the generalizability of the results regarding the usefulness 
of indicators. A further strength of this study is that it is 
based on a large dataset. The dataset consists of the treat-
ment trajectories of over 3000 patients from eight mental 
health service providers. It constitutes a representative mix 
of integrated service providers and providers who special-
ize in only outpatient treatment. Patients from various age, 
gender, diagnostic, educational and socio-economic groups 
were included representing the outpatient population well. 
In addition, from a statistical point of view, the sample size 
ensures adequate statistical power for the required analyses. 
We have limited the present analysis to treatments with a 
maximum duration of 2  years, thereby excluding about 
10% of the treatments, which took longer than 2 years to 
complete. Omitting them has likely affected the results. 
The excluded long treatments occurred predominantly in 
221Adm Policy Ment Health (2018) 45:212–223 
1 3
service providers with on average longer treatments. There-
fore, the present results may be a too conservative repre-
sentation of the true differences between service providers, 
as outliers were mostly excluded in service providers with 
poorer results.
A limitation of the study is that comparison of service 
providers is hampered, as their outcomes may be con-
founded by some patient characteristics we did not cor-
rect for, such as previous psychopathology and treatment 
history. Furthermore, the study is limited to short term 
outcome, assessed immediately after the conclusion of 
treatment. One may argue that lengthier, more expensive 
treatments may yield more lasting results in the long run, 
whereas shorter treatments might have a higher relapse/
recurrence rate (Bockting et al. 2005; Vittengl et al. 2007). 
Future studies should broaden the scope by following how 
patients fare in the period after conclusion of treatment. 
This requires the collection of follow-up data, for instance 
6 months or 1 year later regarding psychological health and 
use of (mental) health care. It would be interesting to inves-
tigate how cost-effectiveness and relapse rates are associ-
ated, as more extensive (and expensive) treatments may be 
offset by better results in the long run.
We have included waiting time prior to the treatment in 
the treatment duration. Service providers vary considerably 
in waiting time. The average per service provider ranges 
from 2.1 to 8.4 weeks. One could argue against our choice 
to include waiting time, since being on a waitlist is not the 
same as undergoing treatment. Yet, from the perspective of 
the patient a long waiting time is adverse and does prolong 
the time till improvement or recovery. Thus, for a fair com-
parison between service providers, it is in our opinion cor-
rect to have included waiting time in the duration of treat-
ment variable.
It should be stressed that the purpose of the present 
study was not a formal cost-effectiveness or cost benefit 
analysis, but rather a comparison of patient-oriented per-
formance indicators. The study approached efficiency from 
a patient (duration) and service providers’ (cost) perspec-
tive and the results can only be interpreted in that context. 
Different conclusions may be drawn when effectiveness 
and efficiency are approached from the broader societal 
perspective, which would imply the gathering of extra data 
regarding cost of illness, financial benefits of treatment and 
gains in quality adjusted life years (van Agthoven et  al. 
2014).
For future studies, it would be useful to examine the 
applicability of the effectiveness and efficiency indicators 
on inpatient treatment, as the present study concerned 
predominantly outpatient treatments. Although inpatients 
with severe mental disorders form a relatively small sub-
group in MHS in The Netherlands (about 15%), they put 
a disproportionate burden on the finances, as inpatient 
treatment is up to ten times more expensive. Further-
more, the source of differences in efficiency among treat-
ment providers should be investigated further, to examine 
whether these differences are associated to demographic 
features, institutional culture or factors related to the 
treatment process, as the latter two are key to quality 
improvement and reducing clinical variance. There was 
quite some variation in treatment duration. Future stud-
ies could examine the association between duration of 
treatment and outcome in more detail. For example, by 
investigating whether patients who require lengthier 
treatments differ in baseline characteristics from those 
who require less treatment or whether the lengthiest treat-
ments are predominantly treatment failures.
In times of rising health care costs and finite budgets 
for health care, the quest for more efficient MHS delivery 
is opportune and swift positive results are beneficial to our 
patients. In The Netherlands, most service providers offer 
a standard treatment regime of weekly or biweekly ses-
sions and are—for logistic reasons—not inclined to attune 
the session frequency to the momentary needs of patients. 
More flexibility, for instance by offering more intensive 
treatment in the initial phase or a more varied treatment 
menu (group therapy, e-health applications and blended 
forms) may yield speedier, better, and more lasting results. 
We may improve MHS with quality management, by test-
ing and evaluating such organizational interventions in 
Plan-Do-Study-Act (Deming 2000) cycles.
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